Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. (LAB) reported insider open-market purchases of its common stock by Casdin-affiliated investment entities that are directors and 10% owners. On 11/13/2025, they bought 450,000 shares at a weighted average price of $1.2031 per share. On 11/14/2025, they bought another 250,000 shares at a weighted average price of $1.2392, and on 11/17/2025, they bought 225,000 shares at a weighted average price of $1.2248.
Following these transactions, one indirect position is shown as 62,975,000 shares, with additional direct and indirect holdings of 2,901,062, 13,939,637, and 2,744,219 shares reported for various Casdin-managed funds and Eli Casdin. The filing notes that prices are weighted averages over multiple trades within stated ranges and that the securities of several funds may be deemed beneficially owned by Casdin Capital entities and Eli Casdin.
Standard BioTools (LAB) reported insider open‑market purchases by entities affiliated with Eli Casdin. The filing lists four buys totaling 1,175,000 shares on 11/07 (225,000 at a weighted average $1.1234), 11/10 (275,000 at $1.1706), 11/11 (300,000 at $1.196), and 11/12/2025 (375,000 at $1.1889).
Following these transactions, the Master Fund’s indirectly beneficially owned balance is stated as 62,050,000 shares. Additional positions reported include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares indirectly by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares indirectly by Casdin Private Growth Equity Fund, L.P. The form is filed by more than one reporting person and marks the reporting persons as a director and 10% owner.
Standard BioTools (LAB) reported Q3 2025 results. Revenue from continuing operations was $19.6 million, down from $22.1 million a year ago. Gross profit was $9.5 million. The company posted a net loss of $34.7 million, including a $31.7 million loss from continuing operations and a $3.0 million loss from discontinued operations.
Operating expenses rose, with selling, general and administrative at $26.6 million, research and development at $6.4 million, and restructuring charges of $9.4 million. Cash and cash equivalents were $129.4 million, with $65.5 million in short‑term and $19.5 million in long‑term U.S. Treasury investments.
The SomaScan Business is classified as held for sale and reported as discontinued operations. On June 22, 2025, the company agreed to sell this business to Illumina for up to $425 million, including $350 million in cash at closing and up to $75 million in earnouts. Closing is subject to customary conditions. Shares outstanding were 384,565,414 as of November 2, 2025.
Standard BioTools Inc. furnished an 8-K announcing it issued a press release with selected financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1.
Sections titled “Operational Restructuring” and “Full Year 2025 Revenue Outlook,” along with the forward-looking statement disclaimer, are furnished under Regulation FD. The information in Items 2.02 and 7.01, including Exhibit 99.1, is expressly furnished and not deemed filed under the Exchange Act.
Standard BioTools Inc. has begun a restructuring plan that includes reducing its global workforce by approximately 15%. The company explains that this move is intended to improve operational efficiency and lower operating costs so they better match its current revenue projections, while still supporting its long-term strategic plan.
The company expects to record about $7.5 million in expenses related to this reduction-in-force, mainly for cash severance, termination benefits, and related costs. These costs are expected to be paid over the next several months, and the company notes that actual expenses could differ and that additional costs may arise in connection with the broader operational restructuring.
Casdin-related entities and Eli Casdin reported a purchase of 100,000 shares of Standard BioTools, Inc. common stock at a weighted-average price of $1.2892 per share on 09/09/2025. The filing shows the shares were acquired in multiple transactions within a narrow price range and that the reporting persons hold large indirect positions: the Master Fund is shown as directly owning securities and several affiliated funds and entities are listed as indirect owners, with a reported total of 60,875,000 shares beneficially owned by the Master Fund reporting group after the transaction. The report also discloses direct ownership by Eli Casdin and by two Casdin private growth funds, and notes deputization of Mr. Casdin to represent the reporting persons on the company board.
Casdin-affiliated investment entities reported new open-market purchases of Standard BioTools Inc. common stock. Casdin Partners Master Fund, L.P., which is treated as a director and 10% owner, bought 250,000 shares on September 3, 2025 at a weighted average price of $1.2656 and another 250,000 shares on September 4, 2025 at a weighted average price of $1.2774.
After these transactions, the Master Fund indirectly beneficially owned 60,775,000 shares of Standard BioTools common stock. Footnotes state these securities are held directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin. Separate positions are also reported as held directly by Eli Casdin and by other Casdin private growth equity funds.
Standard BioTools Inc. plans to consolidate its South San Francisco R&D operations into its Singapore facility and implement a reduction-in-force affecting certain U.S. R&D employees, including members of management. The move is part of a broader effort to restructure operating expenses, improve operational efficiency and reduce operating costs while supporting the company’s long-term strategic plan.
The company currently expects expenses related to the reduction-in-force to be approximately $3.6 million, primarily for cash severance, termination benefits and related costs, including about $0.9 million of non-cash expenses from vesting of share-based awards. These costs are expected to be payable over the next several months, and the company notes that actual costs may differ and that the restructuring could adversely affect sales and development activities.
Standard BioTools director and 10% owner entities associated with Eli Casdin reported a series of open‑market purchases of common stock. Casdin Partners Master Fund, L.P. bought 200,000 shares on August 22, 2025 at $1.2634, 200,000 shares on August 25 at a weighted average $1.2409, and 125,000 shares on August 26 at $1.2635.
After these trades, the Master Fund held 60,275,000 shares indirectly for the reporting group. Separate positions include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares held by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares held by Casdin Private Growth Equity Fund, L.P.
Michael Egholm, President & CEO and Director of Standard BioTools Inc. (LAB), reported a transaction dated 08/20/2025 in which 54,919 shares of common stock were disposed (Transaction Code F) at $1.27 per share. The filing states these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on May 20, 2024 and March 21, 2025, previously reported on Form 4s. After the withholding, the reporting person beneficially owns 5,681,366 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Egholm.